Clinical data were collected from medical records, including name, age, gender, preoperative-neutrophil, preoperative-lymphocyte, con-lymphocyte, con-platelet, post-neutrophil, post-lymphocyte, post-platelet, tumor size, tumor site, histopathological tumor grade, dose of gross tumor volume of tumor bed, dose of Clinical Tumor volume 1, dose of Clinical Tumor volume 2, WHO grade, adjuvant treatment methods (chemo-radiotherapy, radiotherapy, chemotherapy, or only surgical resection), and cycles of adjuvant chemotherapy. The endpoints included the OS, progression-free survival (PFS). The calculated methods were as follows: SII = platelets × neutrophils/lymphocytes, NLR = neutrophils/lymphocytes, and PLR = platelets/lymphocytes.

注意:以上内容是从某篇研究文章中自动提取的,可能无法正确显示。



Q&A
请登录并在线提交您的问题
您的问题将发布在Bio-101网站上。我们会将您的问题发送给本研究方案的作者和具有相关研究经验的Bio-protocol成员。我们将通过您的Bio-protocol帐户绑定邮箱进行消息通知。